The first time I took Afrezza––an inhalable fast-acting insulin––in public, it was at Wildair, a small, hip restaurant i…
Oral Medication
Jardiance Approved For Cardiovascular Indication
The U.S. FDA has approved a new use for Jardiance (empagliflozin), a type 2 diabetes treatment from Boehringer Ingelheim…
MannKind Markets Afrezza to People with Type 1 Diabetes
The maker of inhaled insulin Afrezza is betting that relaunching their product and making it a success depends less on d…
Novo Nordisk Drops Oral Insulin Development Projects
According to an article published on Seeking Alpha, Novo Nordisk has decided to make some significant changes in its dru…
Invokana May Increase Risk of Leg and Foot Amputations
The FDA issued a safety communication alerting the public about interim safety results from an ongoing clinical trial th…
The Hugely Inflated Prices of Glumetza and Metformin ER
I may have been very late to the astonishing price increase of Glumetza, but I am, by coincidence, among the first to re…
FDA Revises Labels of SGLT2 Inhibitors
A U.S. FDA safety review has resulted in adding warnings to the labels of a specific class of type 2 diabetes medicines …
Invokana Warning: Diabetes Drug May Increase Risk of Bone Fractures
Several months ago the FDA warned that SGLT2 inhibitors like Invokana may cause diabetic ketoacidosis, a condition that …
The Novo Nordisk Pipeline: An Interview with CMO Todd Hobbs
Todd Hobbs, the chief medical officer for North America at Novo Nordisk, knows diabetes from all angles: as a patient; a…
Do SGLT2 Inhibitors like Invokana Cause Ketoacidosis?
Only a tiny number of cases of diabetic ketoacidosis have been reported with SGLT2 inhibitor treatment, so this is unlik…
